首页> 外文期刊>Molecular cytogenetics >Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines
【24h】

Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines

机译:慢性粒细胞白血病中BCR / ABL1和ABL1下游区域的基因组扩增:CML患者和细胞系的FISH定位研究

获取原文
           

摘要

Background Chronic myeloid leukaemia (CML) is characterized by the expression of the BCR/ABL1 fusion gene, a constitutively activated tyrosine kinase that commonly results from the formation of the Philadelphia (Ph) chromosome after a t(9;22)(q34;q11) or variant rearrangement. The duplication of the Ph chromosome is a recurring abnormality acquired during disease progression, whereas intrachromosomal amplification of BCR/ABL1 is a rare phenomenon and has been associated with imatinib therapy resistance. Archival bone marrow chromosome suspensions from 19 CML patients known to carry more than 1 copy of BCR/ABL1 and 10 CML cell lines were analyzed by fluorescent in situ hybridization with a panel of probes from 9q34.1-qter to investigate whether they carried two identical copies of the Ph chromosome or, instead, one or both Ph contained cryptic imbalances of some regions. Results A duplication of the entire Ph chromosome with no further events involving the derivative 22 was found in 12 patients. In contrast, a sideline with either 1 or 2 isochromosomes of the Ph chromosome was identified in 6 patients but none of the cell lines. In one of the patients a translocation between the distal end of one arm of the isoderivative chromosome 22 and a third chromosome was revealed. 2 patients were found to carry marker structures harbouring high copy number gains of BCR/ABL1 fusion along with a variable part of 9q34 region downstream of ABL1 breakpoint, similarly to the markers present in the imatinib resistant cell line K562. We identified the following regions of amplification: 9q34.1 → q34.2 and 9q34.1 → qter, with a common minimum amplified region of 682 Kb. One of the patients had 5 BCR/ABL1 positive clones with variable level of 9q34 amplifications on a variety of structures, from an isoderivative 22 to tandem duplications. Conclusions These data confirm that the intrachromosomal genomic amplification of BCR/ABL1 that occurs in some CML patients during disease progression also involves amplification of 9q34 gene-rich sequences downstream of ABL1 breakpoint. The variety of rearrangements identified in this relatively small cohort demonstrates that the Ph chromosome is not a stable structure but prone to further rearrangements during disease progression.
机译:背景慢性粒细胞白血病(CML)的特征在于BCR / ABL1融合基因的表达,BCR / ABL1融合基因是一种组成型激活的酪氨酸激酶,通常由在(9; 22)(q34; q11)后形成费城(Ph)染色体形成或变体重排。 Ph染色体的重复是在疾病进展期间获得的复发异常,而BCR / ABL1的染色体内扩增是一种罕见现象,并且与伊马替尼治疗耐药有关。通过与9q34.1-qter的一组探针进行荧光原位杂交,分析了19名已知携带BCR / ABL1拷贝以上的CML患者和10个CML细胞系的档案骨髓染色体悬浮液,以研究它们是否携带两种相同的Ph染色体的副本或一个或两个Ph的副本包含某些区域的隐秘失衡。结果12例患者中发现整个Ph染色体重复,没有涉及衍生物22的进一步事件。相比之下,在6例患者中发现了带有1个或2个Ph染色体同工异体的副细胞,但没有一个细胞系。在其中一名患者中,发现同等衍生染色体22的一只臂的远端与第三条染色体之间发生了易位。与伊马替尼耐药细胞系K562中存在的标记物相似,发现2名患者携带的标记物结构具有高拷贝数的BCR / ABL1融合以及ABL1断点下游9q34区的可变部分。我们确定了以下扩增区域:9q34.1→q34.2和9q34.1→qter,共同的最小扩增区域为682 Kb。其中一名患者具有5个BCR / ABL1阳性克隆,这些克隆在等构型22到串联重复的多种结构上具有可变水平的9q34扩增。结论这些数据证实,某些CML患者在疾病发展过程中发生的BCR / ABL1染色体内基因组扩增还涉及ABL1断点下游的9q34基因富集序列的扩增。在这个相对较小的队列中发现的各种重排表明,Ph染色体不是稳定的结构,但在疾病发展过程中易于进一步重排。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号